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httpClinical signiﬁcance of embolic events in patients
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interventions with or without embolic protection
devices
Bernardo C. Mendes, MD,a Gustavo S. Oderich, MD,a Mark D. Fleming, MD,a Sanjay Misra, MD,b
Audra A. Duncan, MD,a Manju Kalra, MBBS,a Stephen Cha, MS,c and Peter Gloviczki, MD,a
Rochester, Minn
Objective: The purpose of this study was to evaluate the incidence and clinical signiﬁcance of embolic events in patients
undergoing endovascular femoropopliteal interventions with or without embolic protection devices (EPDs).
Methods:We reviewed the clinical data of 566 patients treated by 836 endovascular femoropopliteal interventions for lower
extremity claudication (46%) or critical limb ischemia (54%) from 2002 to 2012. Outcomes were analyzed in 74 patients/
87 interventions performed with EPDs (Spider Rx; Covidien, Plymouth, Minn) and 513 patients/749 interventions
performed without EPDs. TransAtlantic Inter-Society Consensus (TASC) II classiﬁcation, runoff scores, and embolic
events were analyzed. End points were morbidity, mortality, reintervention, patency, and major amputation rates.
Results: Both groups had similar demographics, indications, cardiovascular risk factors, and runoff scores, but patients
treated with EPDs had signiﬁcantly (P < .05) longer lesions (109 6 94 mm vs 85 6 76 mm) and more often had
occlusions (64% vs 30%) and TASC C/D lesions (56% vs 30%). Embolic events occurred in 35 of 836 interventions (4%),
including two (2%) performed with EPD and 33 (4%) without EPD (P[ .35). Macroscopic debris was noted in 59 (68%)
ﬁlter baskets. Embolic events were not associated with lesion length, TASC classiﬁcation, runoff scores, treatment type, or
indication but were independently associated with occlusion. Patients who had embolization required more reinterven-
tions (20% vs 3%; P < .001) and major amputations at 30 days (11% vs 3%; P[ .02). There was no difference in hospital
stay (2.46 4 days vs 1.6 6 2 days; P[ .08), reintervention (2% vs 4%), and major amputation (1% vs 4%) among patients
treated with or without EPD, respectively. The two patients who developed embolization with EPDs had no clinical
sequela and required no reintervention. Most emboli were successfully treated by catheter aspiration or thrombolysis, but
eight patients (24%) treated without EPD required prolonged hospital stay, seven (21%) had multiple reinterventions, one
(3%) had unanticipated major amputation, and one (3%) died from hemorrhagic complications of thrombolysis. Median
follow-up was 20 months. At 2 years, primary patency and freedom from reintervention was similar for TASC A/B and
TASC C/D lesions treated with or without EPDs.
Conclusions: Rates of embolization are low in patients undergoing endovascular femoropopliteal interventions with (4%)
or without (2%) EPD. Embolization is more frequent in patients with occlusions. While emboli in patients with EPD had
no clinical sequel, those treated without EPD required multiple reinterventions in 21% or resulted in major amputation or
death in 3%. Late outcomes were similar in patients treated with or without EPDs. (J Vasc Surg 2014;59:359-67.)Distal embolization is a well-known and feared compli-
cation of percutaneous interventions with potential devas-
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://dx.doi.org/10.1016/j.jvs.2013.07.119devices (EPDs) has been well-accepted for carotid inter-
ventions and in select patients with coronary saphenous
vein graft lesions.3-5 While EPDs have been designed and
clinically tested for these procedures, their use during lower
extremity revascularization has been criticized because of
questionable signiﬁcance of embolic events, increased
cost, and potential risk of complications such as vessel
trauma or entrapment of the ﬁlter basket.6,7
Distal embolization occurs in 1% to 20% of patients
undergoing iliac, femoral, and popliteal interventions.8-10
Clinical presentation is variable, ranging from asymptomatic
emboli to major emboli with limb-threatening ischemia.
Some patients who develop embolization may necessitate
prolonged hospital stay, reinterventions to restore ﬂow into
the occluded artery, and the risk of limb loss has not been
well-described. The purpose of this study was to evaluate
the incidence, predictive factors, and clinical signiﬁcance of
embolic events in patients undergoing endovascular femoro-
popliteal interventions with or without EPDs.359
Fig 1. Double-wire technique of superﬁcial femoral artery intervention with embolic protection. Once true lumen
access is conﬁrmed with passage of a 0.035-inch catheter, a 0.014-inch Spider RX embolic protection device (EPD)
(Covidien, Plymouth, Minn) is loaded inside the 0.035-inch catheter, advanced, and deployed at or below the level of
the knee joint. A 0.018-inch V18 guidewire (Boston Scientiﬁc, Natick Mass) is used as a “buddy wire” to provide
support for interventions done using 0.035-inch system, and to facilitate retrieval of the ﬁlter basket while avoiding
entrapment of the retrieval catheter in the struts of the stent (A). Balloon angioplasty is performed with the EPD in
place (B), followed by deployment of a self-expanding stent (C). Moderate to severe macroscopic debris was captured
in 45% of ﬁlter baskets (D). Panels A-C are reproduced by permission of the Mayo Foundation for Medical Education
and Research. All rights reserved.
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The study was approved by the Institutional Review
Board of the Mayo Clinic. We retrospectively reviewed
the clinical data of consecutive patients treated for chronic
lower extremity arterial insufﬁciency between 2002 and
2012. Indications for endovascular revascularization were
claudication or critical limb ischemia. Patients with acute
or acute on chronic symptoms were excluded from the
study. Endovascular interventions consisted of angioplasty
alone (PTA), angioplasty with primary or secondary stent-
ing (PTAS), and percutaneous atherectomy. Patients who
had hybrid femoral endarterectomy combined with endo-
vascular femoropopliteal intervention were also analyzed.
Demographics, cardiovascular risk factors, medical
treatment, and indications for revascularization were
reviewed. The severity of the infrainguinal arterial occlusive
disease was graded using Rutherford categories 1 (mild
claudication) to 6 (major tissue loss) according to the
reporting standards of the Society for Vascular Surgery
(SVS).11 Ankle-brachial indices were obtained pre- and
postoperatively. Conventional angiography was analyzed
by an independent investigator to determine TransAtlantic
Inter-Society Consensus (TASC) II classiﬁcation, runoff
scores, technical success, and presence of embolic
events.11,12 Pre- and post-treatment completion angiog-
raphy was used to identify emboli location, extent, andresolution after treatment, if any. The presence of macro-
scopic debris on the ﬁlter basket was noted from procedural
notes and/or photographs, when available. The amount of
debris was classiﬁed as none, mild, moderate, and severe,
based on a subjective analysis by the treating physician. A
basket full of debris was considered “severe” and small or
minimal debris was considered “mild.” Any amount of
debris between these two categories was considered
“moderate.”
Technique of embolic protection. Percutaneous
endovascular femoropopliteal interventions were per-
formed under attended local anesthesia with monitored
anesthesia care or general anesthesia. The decision to use
EPD was left at the discretion of the treating physician.
These were favored during atherectomy procedures and
for recanalization of long-segment occlusions, particularly
in those patients with single-vessel runoff. Most commonly
contralateral trans-femoral access was used, and a 5- to 7-F
hydrophilic sheath was positioned in the common femoral
artery (Fig 1). After systemic heparinization and diagnostic
angiography, the femoropopliteal lesion was crossed using
standard technique with angled or straight 0.035-inch
Glidewire (Terumo, Somerset, NJ) and a catheter
support. Re-entrance devices were used selectively in
patients with occlusions after re-entrance was not successful
using catheter and guide wire technique. Once true lumen
access was conﬁrmed by hand injection using 0.035-inch
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mouth, Minn) was advanced via the 0.035-inch catheter
and deployed at or below the level of the knee joint. A
0.018-inch V18 guidewire (Boston Scientiﬁc, Natick,
Mass) was advanced via the 0.035-inch catheter to be used
as a “buddy wire” to provide support for interventions
done using 0.035-inch system. This facilitated advance-
ment of 0.035-inch stents and retrieval of the ﬁlter basket
(Fig 1). After successful endovascular revascularization, the
EPD was retrieved and examined, and baskets with debris
were photographed for documentation. Completion angi-
ography was obtained. Percutaneous closure was per-
formed using a Perclose device (Abbott Vascular, Abbott
Park, Ill).
Deﬁnitions and end points. Primary end point was
presence of embolization, deﬁned by angiographic
evidence of occlusion or ﬁlling defect in a previously patent
artery or branch distal to the treated segment. Secondary
end points were presence of macroscopic debris on the
ﬁlter basket, mortality, morbidity, reintervention, patency,
and major amputation rates. Early postprocedure events
were deﬁned as occurring within the ﬁrst 30 days or within
hospital stay if longer than 30 days. Reinterventions and
major amputations were analyzed to determine their rela-
tionship to the embolic event. Technical success was
deﬁned as <30% residual stenosis on completion angiog-
raphy. Immediate postembolization treatment, need for
additional procedures, and ﬁnal resolution of the emboliza-
tion were recorded. For patients treated with EPD, tech-
nical problems related to ﬁlter deployment or retrieval
were noted. Patency rates and freedom from reinterven-
tions were deﬁned using the proposed reporting standards
of the SVS.11
Statistical analysis. Outcomes were analyzed in
patients treated with or without EPDs (Spider Rx; Covi-
dien). Continuous variables were reported as mean and
standard deviation, and categorical variables as frequency
and percentages. Time-dependent outcomes were esti-
mated by the Kaplan-Meier method and differences were
determined by log rank test. Univariate and multivariate
logistic regression analysis were performed to identify
predictors of embolization. Results were reported as
percent or odds ratio with 95% conﬁdence interval. The
Pearson c2 or Fisher exact test was used for analysis of
categorical variables. Differences between means were
tested with two-sided t-test, the Wilcoxon rank sum test, or
the Mann-Whitney test. A value of P < .05 was used to
determine statistical signiﬁcance.
RESULTS
Patient characteristics. A total of 566 patients were
treated with 836 femoropopliteal endovascular interven-
tions during the study period. Treatment of the contralat-
eral limb was performed in 99 patients, whereas 171 were
reinterventions in a previously treated limb. Of the 836
interventions, 74 underwent 87 interventions (10%) using
EPDs, and 513 patients had 749 (90%) interventions per-
formed without EPDs. There were 322 (57%) male and244 (43%) female patients with a mean age of 726 11 years
(range, 28-105 years). Demographics, indications for
revascularization, and cardiovascular risk factors were
similar in both groups, with the exception of more patients
with hyperlipidemia in the EPD group (85% vs 73%; P <
.02) and more patients with chronic kidney disease stage
III to V in the non-EPD group (24% vs 10%; P < .01;
Table I). There were more patients in use of clopidogrel in
the EPD group as compared with the non-EPD group
(43% vs 23%; P < .001).
TASC classiﬁcation, extent of disease, and runoff
scores. Interventions were performed for native artery
lesions in 604 cases (72%) or to treat femoropopliteal reste-
nosis in 232 (28%). Patients in the EPD group had signif-
icantly more extensive disease as compared with those
treated without distal protection. The EPD group had
longer lesions (109 6 94 mm vs 85 6 76 mm; P < .03)
and more often had interventions performed for occlusions
(64% vs 30%; P < .001) and for TASC II C/D lesions (56%
vs 30%; P < .001). Runoff scores were similar for both
groups (4.4 6 3 vs 4.7 6 3; P ¼ .3), respectively
(Table II).
Indications for EPDs. Selection of embolic protection
evolved during the study but was left at the discretion of the
treating physician. Sixty-four (74%) interventions with EPD
were performed by the senior author (G.O.). In the ﬁrst 17
cases, EPD was used primarily for recanalization of long
occlusions in patients with single-vessel runoff or for athe-
rectomy. Since 2010, >90% of the interventions performed
by the senior author (G.O.) were done with EPD, including
all patients undergoing recanalizations and those who had
single-vessel runoff or required atherectomy.
Procedural characteristics. Balloon angioplasty was
used in 822 (98%) interventions and primary or secondary
stenting using self-expandable stents in 367 (44%). The
mean number of stents was 1.8 (range, 1-8). Total treat-
ment segment averaged 145 6 107 mm (range, 10-
510 mm). Atherectomy was used in 38 interventions (5%)
and self-expandable stent grafts (Viabahn; W. L. Gore,
Flagstaff, Ariz) in 30 (4%). A hybrid approach with femoral
endarterectomy, patch angioplasty, or interposition graft
was performed in 49 interventions (6%).
Patients with EPD were more often treated with bare
metal self-expandable stents (61% vs 42%; P < .001),
stent grafts (10% vs 3%; P < .01), and atherectomy
(14% vs 4%; P < .001), with a similar number of hybrid
procedures in both groups (7% vs 6%; P ¼ .8; Table II).
Total treatment length (198 6120 mm vs 138 6
103 mm; P < .0001) was longer in the EPD group as
compared with patients treated without EPD, respec-
tively. Technical success was achieved in 93% of the inter-
ventions, with no differences between the groups. The
diameter of the EPD varied from 3 mm to 7 mm, and
a 6 mm SpiderRx was used in 38% of cases. Two patients
(2.3%) had decreased ﬂow caused by the EPD. In one
patient, ﬁlter retrieval was difﬁcult using the 0.014 wire,
which prompted routine use of the double-wire tech-
nique described in Fig 1.
Table I. Demographics, clinical presentation, cardiovascular risk factors, and preadmission medications of patients treated
for chronic limb ischemia by percutaneous interventions with embolic protection device (EPD) or without EPD (No EPD)
All interventions
(n ¼ 836)
EPD
(n ¼ 87)
No EPD
(n ¼ 749) P value
Demographics
Age, years 72 6 11 70 6 10 72 6 11 .06
Female 368 (44) 31 (36) 337 (45) .1
Clinical presentation
Lower extremity claudication 380 (46) 48 (55) 332 (44) .07
Critical limb ischemia 456 (54) 39 (45) 417 (56) .07
Cardiovascular risk factors
Hypertension 714 (86) 74 (85) 640 (86) .9
Cigarette smoking 577 (69) 60 (69) 517 (69) 1
Hyperlipidemia 621 (74) 74 (85) 547 (73) .02
Coronary artery disease 436 (52) 44 (51) 392 (52) .75
Chronic kidney disease stage $III 187 (22) 9 (10) 178 (24) .004
Diabetes 417 (50) 36 (41) 381 (51) .09
Baseline creatinine, mg/dL 1.4 6 1.3 1.2 6 1.2 1.5 6 1.3 .08
Preadmission medications
Any antiplatelet therapy 649 (78) 66 (76) 583 (78) .7
ASA 589 (70) 62 (71) 527 (70) .9
Clopidogrel 211 (25) 37 (43) 174 (23) <.001
Coumadin 127 (15) 18 (21) 109 (15) .13
Statins 540 (65) 62 (71) 478 (64) .17
Ezetimibe 71 (8) 8 (9) 63 (8) .8
Nitrates 158 (19) 21 (24) 137 (18) .19
Calcium channel blockers 225 (27) 23 (26) 202 (27) .92
Angiotensin-converting-enzyme inhibitor 498 (60) 57 (66) 441 (59) .23
b-blockers 543 (65) 56 (64) 487 (65) .9
Diuretics 426 (51) 48 (55) 378 (50) .67
ASA, American Society of Anesthesiologists.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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ventions (4%), including two (2%) performed with EPD
and 33 (4%) without EPD (P ¼ .35). Presence of occlusion
was the only predictor for embolization by univariate anal-
ysis (Supplementary Table, online only). Use of bare metal
stents, angioplasty, or atherectomy was not associated with
embolization. The location of emboli was at distal tibial
vessels in 19 cases (54%), proximal tibial vessels in 11
(31%), below-knee popliteal artery or tibioperoneal trunk
in three (9%), and superﬁcial femoral artery in two (6%). Of
the 35 patients with embolization, three presented with
subacute symptoms with duration of 2 to 6 weeks. A total
of 23 embolizations were identiﬁed for TASC A/B lesions
(4.2%), for an embolization rate of 2.6% with and 4.3%
without EPD. For TASC C/D lesions, 12 embolic events
were noted, for an embolization rate of 2.1% with and 5%
without EPD.
Two patients had embolization with EPD. The exact
mechanism of embolization could not be determined,
but may represent failure of the EPD, including malposi-
tion, undersizing, or dislodgement during retrieval; or
formation of platelet or thrombus emboli beyond the ﬁlter
device. Both patients had moderate debris in the ﬁlter
basket. In one patient, it is likely that embolization
occurred during retrieval of the EPD. In the second
patient, the exact mechanism could not be determined,but complete resolution with tissue plasminogen activator
(t-PA) indicates a thrombus emboli, which may have orig-
inated beyond the EPD due to stagnant ﬂow or inadequate
systemic heparinization.
In the 33 patients who had embolization after interven-
tions without EPD, 25 were treated immediately with t-PA
infusion in 16 and catheter aspiration in 10. Other adjunc-
tive measures were intra-arterial nitroglycerin in two
patients, angioplasty and stenting at the location of the
embolization in two patients, and retrieval of the embolic
material using an EPD or over-the-wire embolectomy in
one patient each. Of the patients who underwent imme-
diate treatment, 12 had complete resolution, six had
improvement, and seven had no change. Among the 13
patients with persistent emboli, seven were started in
continuous catheter-directed thrombolysis using t-PA. A
total of 11 reinterventions for thrombolytic recheck or cath-
eter exchange were required among these seven patients. At
the time of the last thrombolytic recheck, ﬁve had complete
resolution, one had improvement, and one had no change.
Eight patients (23%) with emboli underwent no additional
treatment, including seven patients who had small emboli,
which was not considered to be clinically signiﬁcant and
was associated with reﬁlling via other collateral branches.
Of the 35 patients who had emboli, complete resolution
was noted in 18 (51%), partial resolution in seven (20%),
Table II. Angiographic and procedural characteristics of patients treated for chronic limb ischemia by percutaneous
interventions with embolic protection device (EPD) or without EPD (No EPD)
All interventions
(n ¼ 836)
EPD
(n ¼ 87)
No EPD
(n ¼ 749) P value
Lesion characteristics
Length of stenosis, mm 88 6 78 109 6 94 85 6 76 .02
Presence of occlusion 272 (34) 55 (64) 217 (30) <.001
Length of occlusion, mm 119 6 95 121 6 114 118 6 89 .86
SVS runoff score 4.7 6 2.7 4.4 6 2.6 4.7 6 2.7 .27
TASC II
TASC A 294 (35) 20 (23) 274 (37) .02
TASC B 253 (30) 18 (21) 235 (31) .05
TASC C 197 (24) 31 (36) 166 (22) <.01
TASC D 72 (9) 17 (20) 55 (7) <.001
Treatment
Balloon angioplasty 822 (98) 84 (97) 738 (90) .2
Bare metal stenting 367 (44) 53 (61) 314 (42) <.001
Self-expanding stent grafts 30 (4) 9 (10) 21 (3) <.01
Atherectomy 38 (5) 12 (14) 26 (4) <.001
Hybrid procedure 49 (6) 6 (7) 43 (6) .8
Vessel treated
Femoral 747 (89) 83 (95) 664 (89) .06
Popliteal 387 (46) 57 (65) 330 (44) <.001
Femoral + popliteal 312 (37) 53 (61) 259 (35) <.0001
Concomitant tibial 133 (16) 12 (14) 121 (16) .6
Concomitant iliac 84 (10) 13 (15) 71 (10) .1
Concomitant infrarenal aorta 4 (0.5) 3 (3.4) 1 (0.1) <.01
SVS, Society for Vascular Surgery; TASC, TransAtlantic Inter-Society Consensus.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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patients who had small emboli left untreated developed
clinical sequelae. Macroscopic debris was noted in 59
(68%) ﬁlter baskets, 39 of which were described as
moderate or severe amount of debris (45%; Fig 1).
Early outcomes. Patients with embolic events required
more early reinterventions (20% vs 3%; P < .001) and early
major amputations (11% vs 3%; P ¼ .02) than those who
did not have an embolization, with no difference in length
of hospital stay (2.8 6 6 days vs 2.3 6 4 days; P ¼ .5).
There was no difference in hospital stay (2.4 6 4 days vs
1.6 6 2 days; P ¼ .08), reintervention (2% vs 4%; P ¼
.4), and major amputation (1% vs 4%; P ¼ .3) among
patients treated with or without EPD, respectively. None
of the two patients who had small emboli with EPD devel-
oped clinical sequelae or required reintervention. In the
group treated without EPD, eight (24%) patients required
prolonged hospital stay, seven (21%) had reinterventions
performed to restore lower extremity ﬂow, and one (3%)
had major unanticipated amputation. This patient devel-
oped embolization of large calciﬁc material to the tibioper-
oneal trunk and proximal anterior tibial artery, which was
not felt to be amenable to endovascular maneuvers by the
treating physician, resulting in acute ischemia and leading
to below-knee amputation. One patient died from hemor-
rhagic complications of thrombolytic therapy used to treat
an embolic event. The patient was an 84-year-old female
with multiple comorbidities, morbid obesity, end-stage
renal disease on peritoneal dialysis, and chronic atrial
ﬁbrillation, who developed puncture-related hemorrhageand multisystem organ failure during thrombolytic therapy.
The patient expired after care was withdrawn per advanced
directives and family request.
Late outcomes. Mean follow-up was 14 months for
the EPD group (range, 0-43 months) and 21 months for
patients treated without EPD (range, 0-114 months).
Late outcomes were analyzed separately in patients with
TASC A/B and TASC C/D lesions. Primary patency at
2 years was 70% for TASC A/B lesions, with no difference
among patients treated with (68%) or without EPD (70%;
P ¼ .4). Freedom from reintervention was also similar
after 2 years (68% for the EPD vs 72% for the non-EPD
group; P ¼ .3). Primary patency at 2 years for TASC
C/D lesions was 57%, and was signiﬁcantly lower than
patients with TASC A/B lesions (P < .01). There were no
differences in primary patency rates at one year in patients
treated with (81%) or without EPD (68%; P ¼ .5).
Freedom from reintervention was also similar after
18 months (83% for the EPD vs 67% for the non-EPD
group; P ¼ .4). Comparing patients who had embolic
events with those who did not, there were no differences
in primary patency and freedom from reintervention after
1 year for TASC A/B (86% vs 78% and 86% vs 80%) or
TASC C/D lesions (67% vs 70% and 73% vs 76%),
respectively (P ¼ .4; Fig 3).
DISCUSSION
Endovascular interventions carry risk of embolization.
Emboli in the carotid and coronary arteries can result in
life-threatening complications or permanent disability.4,13
Fig 2. Example of a case of distal embolization successfully treated with thrombolysis and catheter aspiration. Left
lower extremity selective angiography demonstrates a segmental occlusion of the superﬁcial femoral artery (SFA; A) and
patent tibioperoneal trunk (B). After crossing of the SFA lesion, the angiogram reveals occlusion at the bifurcation of
the tibioperoneal trunk, with compromise of ﬂow to both arteries (C; arrowhead). After catheter aspiration of thrombus
followed by continuous catheter-directed thrombolysis during 8 hours, completion angiography demonstrates
improved ﬂow and patent tibioperoneal trunk (D).
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tions of EPDs when applied to these interventions.
However, in the lower extremities, the clinical signiﬁcance
of distal embolization has not been well described.
Although emboli may result in limb loss or require invasive
treatment, most believe that its frequency is low and that
these events carry little signiﬁcance.8 This study describes
a low frequency of emboli for interventions performed
without embolic protection (4%) and even lower rates for
those who had embolic protection (2%), despite more
occlusions and longer lesions in the latter group. Although
rates of emboli were similar, clinical consequences of
emboli without EPD may be more severe.
The incidence of embolization during femoropopliteal
interventions ranges from 2% to 100%.8,9,14 Prior reports
have shown that clinical examination is a poor indicator
of embolization. The wide variation in embolization rates
in these reports is explained by differences in extent of
disease, lesion type, treatment modality, and diagnostic
method.8,9,15,16 Lam and associates employed continuous
Doppler ultrasound monitoring in 60 patients treated by
endovascular superﬁcial femoral artery interventions.
Embolic signals were noted in the popliteal artery in all
interventions, and were signiﬁcantly more frequent during
stent deployment than during wire crossing or balloonangioplasty.8 In studies that evaluated presence of macro-
scopic debris in ﬁlter baskets, rates of embolization range
from 55% to 100%.10,15-19 We found that two-thirds of
the ﬁlter baskets had macroscopic debris, which was graded
moderate to severe in 45%. This ﬁnding indicates that
completion angiography provides limited assessment of
emboli to smaller branches.
Angiographic evidence of embolization during lower
extremity interventions ranges from 0% to 30%. Shrikkande
and colleagues reported a large series of 2137 lesions
treated in 1029 patients, with only 34 embolic events
(1.6%).9 The rate of embolization was signiﬁcantly higher
(22%) among patients treated with atherectomy devices.
Higher rates were also seen for patients with occlusions
treated by recanalization, in-stent restenosis, and TASC
C and D lesions. In that report, patency was restored in
32 of 34 cases, similar to our report. There were no differ-
ences in patency rates among patients who had or did not
have embolic events. The authors concluded that selective
use of EPDs should be considered in patients undergoing
atherectomy, and in those treated for occlusions, TASC
C and D lesions, or in-stent restenosis.9
Current evidence on the use of EPDs for lower
extremity interventions remains scarce. The PROTECT
registry reported the results of a single-center prospective
Fig 3. Kaplan-Meier estimates of primary patency (A) and freedom from reintervention (B) in patients treated for
chronic limb ischemia by percutaneous interventions with embolic protection device (EPD) or without EPD (No EPD).
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ment for infrainguinal occlusive disease with EPDs.16
Similar to our report, 55% of the ﬁlter baskets had macro-
scopic debris, with higher rates among patients treated by
atherectomy (100%). There were no complications with
ﬁlter retrieval, and one side-branch embolization proximal
to the ﬁlter was noted.16 A prospective, single-center study
by Müller-Hülsbeck and associates evaluated the perfor-
mance of the FilterWire EZ Embolic Protection System
(Boston Scientiﬁc, Mountain View, Calif) in 30 superﬁcial
femoral artery interventions. There were no device-related
complications, and macroscopic debris was found in 90% of
ﬁlters. Microscopic analysis demonstrated a particle size
ranging from 90 to 2000 mm, with the major components
of emboli being platelets, erythrocytes, inﬂammatory cells,
extracellular matrix, and cholesterol.17 Spiliopoulos and
associates have reported very low rates of embolization
(0.57%) among 3147 percutaneous interventions. Their
use of embolic protection in patients with subacutepresentation of 3 to 6 months was suggested as a possible
explanation for their low embolization rates.20 However,
the study lacked information on the number of lesions
that presented with subacute symptoms, number of
patients treated with EPD, and speciﬁc outcomes with or
without EPD; reporting of these numbers is encouraged
to support the authors’ opinion. Karnabitidis and
colleagues demonstrated the use of the Spider FX device
in 48 patients who underwent endovascular revasculariza-
tion of infra-aortic lesions. There were three device failures,
which included one side-branch occlusion, one distal
embolization, and one device-related vasospasm. A particle
greater than 1 mm was detected in 70% of the baskets, with
similar histologic characteristics as the aforementioned
study. Increased lesion length, reference vessel diameter,
acute thrombosis, and vessel occlusion were signiﬁcantly
associated with higher amounts of particles on the ﬁlter.15
Patients that present with subacute symptoms may have
lesions that are at higher risk for embolic events. Shammas
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during treatment of recent onset (<6 months) occlusions.
In that study, thrombus was identiﬁed by intravascular
ultrasound in 94% of 17 patients. Embolization was identi-
ﬁed in 18% of patients. The authors concluded that a throm-
botic component is present in most patients with recent
onset occlusion, with a higher embolization risk for these
lesions. Although we have not analyzed the duration of
symptoms for all interventions in our series, the low number
of patients with subacute presentation (9%) suggests that
this accounts for a minority of all embolic events.21
In this study, patients treated with EPDs had worse
anatomical characteristics, including longer lesions and
more occlusions, for which higher rates of embolization
would be expected. Nonetheless, rates of embolization
were lower (2% vs 4%) than what was observed among
patients treated without EPDs, although this did not reach
statistical signiﬁcance. Most importantly, the two patients
who had embolization with EPD had no clinical conse-
quence and did not require reintervention. Conversely,
emboli in the group treated without EPD was associated
with more reinterventions (21%), one unanticipated major
amputation, and one death. Although there was no signif-
icant relation between TASC classiﬁcation and embolic
events, the presence of occlusion was a risk factor as
demonstrated in other studies.8,9,22 Our study did not
show major complications directly related to the ﬁlter.
One question is whether the emboli have any impact
on long-term results of revascularization. There were no
differences in primary patency rates or freedom from rein-
tervention after stratiﬁcation of patients according to TASC
classiﬁcation. Although presence of embolization was asso-
ciated with more early reinterventions, these patients were
not at higher risk of late reinterventions or loss of primary
patency.
A few technical considerations deserve mention when
using EPDs for lower extremity interventions. Often, these
devices are selected in patients with difﬁcult lesions, occlu-
sions, and dense calciﬁcations. Because EPDs are designed
over a 0.014-inch platform, these devices often lack
enough guide wire support to advance 0.035-inch balloons
and stents over difﬁcult lesions. In addition, retrieval of the
device can be problematic. In a patient treated by stenting,
it may be difﬁcult to advance the retrieval catheter over
long stented segments over the 0.014-inch wire because
the catheter may catch in the stent struts. We found that
the use of a two-wire technique with the 0.014-inch Spider
RX EPD and a 0.018-inch “buddy wire” provides excellent
support to advance 0.035-inch balloons, stents, and to
retrieve the device (Fig 1). The Spider Rx device has size
range of 3 mm to 7 mm and a working length of
320 cm, allowing use of long shaft balloons and stents
via contralateral femoral approach.
This study has several limitations, notably the retro-
spective analysis of consecutive patients treated in a non-
randomized fashion. Selection of EPDs was based on
physician preference and did not follow a speciﬁc algo-
rithm. There were differences between treatment groups,although ultimately these favored patients treated without
EPD and were not signiﬁcantly related to primary end
points. It was not possible to determine if the technique
used for recanalization was either subintimal or intralumi-
nal. We did not perform an analysis of symptoms duration
before intervention and presence of subacute thrombotic
occlusion; however, only one patient who had emboliza-
tion had angiographic evidence of subacute thrombus,
therefore, it is unlikely that this would be a signiﬁcant
factor in our series. Most interventions performed with
EPD were done by a single operator, and it is possible
that technical aspects related to this individual affected
outcomes. The power of the study was impaired by the
small number of interventions performed with EPD, which
likely affected the ability to detect small statistical differ-
ences between groups. There was no cost-related analysis;
the use of EPDs is known to increase the cost of the proce-
dure (by approximately US $1000) but the impact of
multiple reinterventions, early amputations, and a death
due to embolization is difﬁcult to analyze. Finally, only
one type of EPD was utilized in this investigation; it is
unclear if the evidence found will be extended to other
device designs in the same setting.
CONCLUSIONS
In summary, in this single-center, retrospective, non-
randomized study, clinically signiﬁcant embolic events
were uncommon after endovascular femoropopliteal inter-
ventions performed with or without EPDs. Embolic events
were associated with recanalization of chronic total occlu-
sions. Although patients treated with EPDs had more
advanced lesions, rates of embolization were lower in this
group, although this did not reach statistical signiﬁcance.
Importantly, none of the patients who had emboli with
EPD developed clinical sequelae or required reinterven-
tion, whereas one in four patients who developed emboli-
zation without EPD required escalating level of care. At
the present time, these devices cannot be recommended
for routine use but should be considered in patients with
occlusions and in those undergoing atherectomy, based
on results of this study and other reports. Further analysis
with a larger subset of patients, in a prospective, multi-
center, randomized setting is desirable to better under-
stand the role of EPDs in lower extremity endovascular
revascularizations.
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Supplementary Table (online only). Univariate analysis of predictors of embolization in patients treated for chronic
limb ischemia by percutaneous interventions with embolic protection device (EPD) or without EPD
All interventions
(n ¼ 836)
Embolism
(n ¼ 35)
No embolism
(n ¼ 801) P value
Preoperative characteristics
Use of EPD 10 6 11 .4
Presence of occlusion 34 51 33 .04
Previous stent occlusion 3 9 3 .08
Previous bypass occlusion 1 0 1 .5
Length of occlusion, mm 119 6 95 142 6 94 117 6 95 .3
Length of stenosis, mm 88 6 78 69 6 42 88 6 79 .2
TASC II .7
A/B 67 64 67
C/D 33 36 33
Operative characteristics
Angioplasty 98 94 99 .06
Bare metal stent 44 51 44 .4
Atherectomy 5 9 4 .2
Length treated 145 6 107 134 6 94 146 6 107 .6
TASC, TransAtlantic Inter-Society Consensus.
data as percentage.
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